Pd35-02 Impact of 2012 United States Preventive Services Task Force Statement on Prostate Cancer Screening, Detection and Presentation in Men Under the Age of 70 at Kaiser Permanente Northern California
Year: 2019
Type: article
Study design: Observational Study
Abstract: You have accessJournal of UrologyProstate Cancer: Detection & Screening VI (PD35)1 Apr 2019PD35-02 IMPACT OF 2012 UNITED STATES PREVENTIVE SERVICES TASK FORCE STATEMENT ON PROSTATE CANCER SCREENING, DETECTION AND PRESENTATION IN MEN UNDER THE AGE OF 70 AT KAISER PERMANENTE NORTHERN CALIFORNIA Joseph Presti*, Stacey Alexeeff, Brandon Horton, Stephanie Prausnitz, and Andrew Avins Joseph Presti*Joseph Presti* More articles by this author , Stacey AlexeeffStacey Alexeeff More articles by this author , Brandon HortonBrandon Horton More articles by this author , Stephanie PrausnitzStephanie Prausnitz More articles by this author , and Andrew AvinsAndrew Avins More articles by this author View All Author Informationhttps://doi.org/10.1097/01.JU.0000556334.01958.77AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVES: To determine how the 2012 United States Preventive Services Task Force (USPSTF) Prostate Cancer Screening recommendations altered the rates of PSA screening, prostate biopsy, incident prostate cancer detection, and stage IV at presentation in screen-eligible men in Kaiser Permanente Northern California (KPNC). METHODS: This is a retrospective study spanning the years 2010 to 2015, in screen-eligible (over 400,000) KPNC members (African American men ages 45-69 and all other men ages 50-69) with no prior history of prostate cancer. We compared the annual rates of PSA testing, prostate biopsy, age and race adjusted incident prostate cancer detection, and age and race adjusted stage IV cancer at presentation between the pre-guideline period, 2010 and 2011; and the post-guideline period, 2014 and 2015. RESULTS: Following the 2012 USPSTF statement, relative screening rates declined 23.4% (95% CI 23.0-23.8%), biopsy rates declined 64.3% (95% CI 62.9-65.6%), incident prostate cancer detection rates declined 53.5% (95% CI 50.1-56.7%) resulting in 1871 fewer incident cancers detected, and metastatic cancer rates increased 36.9% (95% CI 9.5%-71.0%) resulting in 75 more incident stage IV cancers detected. CONCLUSIONS: Following the USPSTF 2012 Statement, PSA screening, biopsy and incident prostate cancer detection rates significantly decreased while rates of metastatic disease significantly increased in men under the age of 70. Source of Funding: The Permanente Medical Group Physician Researcher Program Mill Valley, CA; Oakland, CA© 2019 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 201Issue Supplement 4April 2019Page: e650-e650 Advertisement Copyright & Permissions© 2019 by American Urological Association Education and Research, Inc.MetricsAuthor Information Joseph Presti* More articles by this author Stacey Alexeeff More articles by this author Brandon Horton More articles by this author Stephanie Prausnitz More articles by this author Andrew Avins More articles by this author Expand All Advertisement PDF downloadLoading ...
Source: The Journal of Urology
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2942284277